ВТОРИЧНАЯ ПРОФИЛАКТИКА ИНСУЛЬТА ФАРМАКОЭКОНОМИЧЕСКИЕ АСПЕКТЫ ПРОБЛЕМЫ

1. Воробьев П.А., Авксентьева М.В., Юрьев А.С., Сура М.В. Клинико-экономический анализ (оценка, выбор медицинских технологий и управление качеством медицинской помощи). М.: Издательство «Ньюдиамед», 2004. 404 с.

2. Гусев Е.И., Скворцова В.И., Стаховская Л.В., Киликовский В.В., Айриян Н.Ю. Эпидемиология инсульта в России//Consilium medicum 2003; 5(5).

3. Явелов И.С., Грацианский Н.А. Российский регистр острых коронарных синдромов: лечение и исходы в стационаре при остром коронарном синдроме с подъемами сегмента ST1//Кардиология 2004; 4: 4-13.

4. Яковлев В.Б., Яковлева М.В. Тромбоэмболия легочной артерии: патофизиология, диагностика, лечебная тактика//Consilium medicum 2005; 7(6).

5. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials//Lancet 2003; 362: 1527-1535.

6. Dahlof В., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol//Lancet 2002; 359: 995-1003

7. Gaziano T. Cardiovascular disease in the developing world and its cost-effective management//Cardiology Rounds 2005; 9(2): 3547-3553.

8. Nieminen M., Brutsaert D., Dickstein K., et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population//Eur. Heart J. 2006; 27: 2725 -2736.

9. Sarti C., Stegmayr В., Tolonen H., et al. Are changes in mortality from Stroke caused by changes in Stroke event rates or case fatality? Results from the WHO MONICA Project//Stroke 2003; 34: 1833.

10. Schrader J., Luders S., Kulschewski A., et al. Morbidity and mortality after Stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES)//Stroke 2005; 36: 1218-1226.

11. Staessen J.A., Fagard R., Thijs L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension//Lancet 1997; 350: 757-64.

12. Trenkwalder P., Elmfeldt D., Hofman A. et al. The Study of Cognition and Prognosis in the Elderly (SCOPE) -Major CV events and stroke in subgroups of patients//Blood Pressure 2005; 14: 31-37.

13. Weber M.A., Julius S., Kjeldsen S.E., et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial//Lancet 2004; 363: 2032-2034.

14. World Health Organization. Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva (Switzerland): World Health Organization; 2001.